A practical reference on IGF-1: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-16 and is reviewed periodically as new material appears.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Discovered in 1861 by Aleksandr Butlerov, the formose reaction is a set of two reactions converting formaldehyde (CH2O) to a mixture of simple sugars. Formaldehyde is an intermediate in the oxidation of simple carbon molecules (e.g. methane) and was likely present in early Earth's atmosphere. The first reaction is the slow conversion of formaldehyde (C1 carbon) to glycolaldehyde (C2 carbon) and occurs through an unknown mechanism. The second reaction is the faster and autocatalytic formation of higher weight aldoses and ketoses. The kinetics of the formose reaction are often described as autocatalytic, as the alkaline reaction uses lowest molecular weight sugars as feedstocks or input molecules into the reaction. Self-organized autocatalytic networks, like the formose reaction, would allow for adaptation to changing prebiotic environmental conditions. As a proof-of-concept, Robinson and colleagues demonstrated how changing environmental conditions and catalyst availability can impact the resultant sugar products. In the past, many researchers have suggested the importance of this reaction for abiogenesis and the origins of metabolism because it can lead to ribose. Ribose is a building block of RNA and an important precursor in proto-metabolism. However, there are limitations for the formose reaction to be the chemical origin of sugars including the low chemoselectivity for ribose and high complexity of the final reaction mixture.
{\displaystyle \overbrace {{\vphantom {\frac {}{}}}\underbrace {\frac {\partial \mathbf {u} }{\partial t}} _{\text{Variation}}+\underbrace {{\vphantom {\frac {}{}}}(\mathbf {u} \cdot \nabla )\mathbf {u} } _{\begin{smallmatrix}{\text{Convective}}\\{\text{acceleration}}\end{smallmatrix}}} ^{\text{Inertia (per volume)}}=\overbrace {{\vphantom {\frac {\partial }{\partial }}}\underbrace {{\vphantom {\frac {}{}}}-\nabla w} _{\begin{smallmatrix}{\text{Internal}}\\{\text{source}}\end{smallmatrix}}+\underbrace {{\vphantom {\frac {}{}}}\nu \nabla ^{2}\mathbf {u} } _{\text{Diffusion}}} ^{\text{Divergence of stress}}+\underbrace {{\vphantom {\frac {}{}}}\mathbf {g} } _{\begin{smallmatrix}{\text{External}}\\{\text{source}}\end{smallmatrix}}.}
In March 2022, 777 Partners bought 100% of Standard Liège in the Belgian Pro League for €55 million. The fans protested in September 2023 over what they believed to be a lack of investment and ambition. In December 2023, Standard Liège was given an indefinite transfer ban by national authorities for alleged delays in paying taxes, salaries and transfer fees. In May 2024, former Standard owner Bruno Venanzi and the former owners of the club's Stade Maurice Dufrasne demanded the seizure of 777's assets in Belgium over alleged non-payment. Later that month in protest against 777, Standard fans blocked the team bus from leaving the training center before a game against Westerlo, leading to the game being postponed. A court ruled that 777's assets in Belgium could be seized. After 777's soccer clubs passed into ownership of A-CAP, the latter put Standard up for sale in September 2024. In June 2025, the ownership transferred to Giacomo Angelini, alongside a capital increase of €28.7 million.
From a biochemical perspective, other challenges that immunoliposome therapies face are drug instability due to the phospholipid bilayer and the known possibility for hepatotoxicity. From a manufacturing perspective, designing liposome drug delivery systems at an industrial scale can present a challenge due to the complexity of these drug release mechanisms and their related biosafety.
Sources: en.wikipedia.org
== Further reading == Fitzgerald J, Bateman JF (September 2001). "A new FACIT of the collagen family: COL21A1". FEBS Letters. 505 (2): 275–280. doi:10.1016/S0014-5793(01)02754-5. PMID 11566190. Chou MY, Li HC (March 2002). "Genomic organization and characterization of the human type XXI collagen (COL21A1) gene". Genomics. 79 (3): 395–401. doi:10.1006/geno.2002.6712. PMID 11863369.
Vaginal infections or diseases include yeast infection, vaginitis, sexually transmitted infections (STIs) and cancer. Lactobacillus gasseri and other Lactobacillus species in the vaginal flora provide some protection from infections by their secretion of bacteriocins and hydrogen peroxide. The healthy vagina of a woman of child-bearing age is acidic, with a pH normally ranging between 3.8 and 4.5. The low pH prohibits growth of many strains of pathogenic microbes. The acidic balance of the vagina may also be affected by semen, pregnancy, menstruation, diabetes or other illness, birth control pills, certain antibiotics, poor diet, and stress. Any of these changes to the acidic balance of the vagina may contribute to yeast infection. An elevated pH (greater than 4.5) of the vaginal fluid can be caused by an overgrowth of bacteria as in bacterial vaginosis, or in the parasitic infection trichomoniasis, both of which have vaginitis as a symptom. Vaginal flora populated by a number of different bacteria characteristic of bacterial vaginosis increases the risk of adverse pregnancy outcomes. During a pelvic exam, samples of vaginal fluids may be taken to screen for sexually transmitted infections or other infections. Because the vagina is self-cleansing, it usually does not need special hygiene. Clinicians generally discourage the practice of douching for maintaining vulvovaginal health. Since the vaginal flora gives protection against disease, a disturbance of this balance may lead to infection and abnormal discharge.
Since this single emitted neutrino carries the entire decay energy, it has this single characteristic energy. Similarly, the momentum of the neutrino emission causes the daughter atom to recoil with a single characteristic momentum. The resulting daughter nuclide, if it is in an excited state, then transitions to its ground state. Usually, a gamma ray is emitted during this transition, but nuclear de-excitation may also take place by internal conversion. Following capture of an inner electron from the atom, an outer electron replaces the electron that was captured and one or more characteristic X-ray photons is emitted in this process. Electron capture sometimes also results in the Auger effect, where an electron is ejected from the atom's electron shell due to interactions between the atom's electrons in the process of seeking a lower energy electron state. Following electron capture, the atomic number is reduced by one, the neutron number is increased by one, and there is no change in mass number. Simple electron capture by itself results in a neutral atom, since the loss of the electron in the electron shell is balanced by a loss of positive nuclear charge. However, a positive atomic ion may result from further Auger electron emission. Electron capture is an example of weak interaction, one of the four fundamental forces.
=== Outcome and management === The liver injury due to the carbapenems is usually mild and self-limited. Rarely, the carbapenems can cause a clinically apparent acute cholestatic hepatitis that is usually self-limiting and not requiring therapy or intervention. In patients with vanishing bile duct syndrome, corticosteroids are often used but have not been shown to be beneficial and are best avoided. Some patients may benefit from symptomatic therapy of the pruritus associated with cholestasis using antihistamines, ursodiol, or cholestyramine. Little information is available on possible cross-sensitivity to liver injury among the different betalactam antibiotics, but patients with clinically apparent liver injury due to imipenem should probably avoid the other carbapenems.
=== Chengdu Uprising === By 1949, it was clear that the communist forces under the People's Liberation Army would triumph in the Chinese Civil War. In January, Liu Wenhui travelled to Nanjing to meet with Chiang Kai-shek and assess the political situation; he concluded that Chiang was losing the war and began preparations for defection. Liu accelerated his plans after the Lanzhou Campaign concluded in August with a communist seizure of the city. He began intensifying contacts with underground communists in Sichuan, including Zhang Zhihe and Peng Dixian, in order to coordinate operations. Chiang had attempted to draw Liu out of Xikang by offering him a position as chairman of the Mongolian and Tibetan Affairs Commission, which was refused by Liu.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.